BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 30269815)

  • 1. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet.
    Zhu W; Feng PP; He K; Li SW; Gong JP
    Biochem Biophys Res Commun; 2018 Oct; 505(2):523-529. PubMed ID: 30269815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
    He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
    Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy.
    Yu X; Hao M; Liu Y; Ma X; Lin W; Xu Q; Zhou H; Shao N; Kuang H
    Eur J Pharmacol; 2019 Dec; 864():172715. PubMed ID: 31593687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation.
    Sui YH; Luo WJ; Xu QY; Hua J
    World J Gastroenterol; 2016 Feb; 22(8):2533-44. PubMed ID: 26937141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation.
    Tang Y; Cao G; Min X; Wang T; Sun S; Du X; Zhang W
    J Physiol Biochem; 2018 Nov; 74(4):503-510. PubMed ID: 30019185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway.
    Li Z; Feng PP; Zhao ZB; Zhu W; Gong JP; Du HM
    Biochem Biophys Res Commun; 2019 Feb; 510(1):20-26. PubMed ID: 30683312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells.
    Chen HW; Yen CC; Kuo LL; Lo CW; Huang CS; Chen CC; Lii CK
    Toxicol Appl Pharmacol; 2020 Apr; 393():114941. PubMed ID: 32126212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of the effect of liraglutide on the correlation between NLRP3 inflammasome and non-alcoholic fatty liver disease].
    Ma ZZ; Ao N; Yang N; Yang J; Jin S; Du C; Du J
    Zhonghua Gan Zang Bing Za Zhi; 2022 Jun; 30(6):624-630. PubMed ID: 36038324
    [No Abstract]   [Full Text] [Related]  

  • 9. Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice.
    Yu Y; Chen D; Zhao Y; Zhu J; Dong X
    Int J Immunopathol Pharmacol; 2021; 35():20587384211036819. PubMed ID: 34399601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet.
    Yang G; Lee HE; Lee JY
    Sci Rep; 2016 Apr; 6():24399. PubMed ID: 27075683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3.
    Ruan S; Han C; Sheng Y; Wang J; Zhou X; Guan Q; Li W; Zhang C; Yang Y
    Int Immunopharmacol; 2021 Nov; 100():108126. PubMed ID: 34492534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice.
    Sun CC; Zhang CY; Duan JX; Guan XX; Yang HH; Jiang HL; Hammock BD; Hwang SH; Zhou Y; Guan CX; Liu SK; Zhang J
    Biochem Biophys Res Commun; 2020 Mar; 523(4):1020-1026. PubMed ID: 31973813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release.
    Pan J; Ou Z; Cai C; Li P; Gong J; Ruan XZ; He K
    Cell Immunol; 2018 Oct; 332():111-120. PubMed ID: 30103942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apigenin ameliorates HFD-induced NAFLD through regulation of the XO/NLRP3 pathways.
    Lv Y; Gao X; Luo Y; Fan W; Shen T; Ding C; Yao M; Song S; Yan L
    J Nutr Biochem; 2019 Sep; 71():110-121. PubMed ID: 31325892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ginsenoside Rg1 Protects against Non-alcoholic Fatty Liver Disease by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammasome Activation.
    Xu Y; Yang C; Zhang S; Li J; Xiao Q; Huang W
    Biol Pharm Bull; 2018 Nov; 41(11):1638-1644. PubMed ID: 30135326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation.
    Liu J; Wang T; He K; Xu M; Gong JP
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8158-8167. PubMed ID: 31599445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK].
    Zhao XY; Zhang LL; Suolang QZ; Yang GY; Li L; Li SB; Chen WW
    Zhonghua Gan Zang Bing Za Zhi; 2014 Nov; 22(11):849-53. PubMed ID: 25531383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
    Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
    Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.